I have read an article [@bib1] with great interest.

I would like to share my opinion with readers regarding this subject. When I rode a taxi in Tokyo, I found a flyer in the car promoting for a clinic that offers cancer gene therapy. The flyer says that some anti-oncogenes, such as p53, that are often depleted or mutated in tumor cells are transduced to the patients' tumor cells *in vivo* to kill the cancer cells. However, in Japan, no gene therapy products have been approved by the regulatory authority, and the number of clinical research in gene therapy performed in Japan is very limited, since it is strictly regulated by legislation and guidelines. I was curious if the aforementioned clinic imports cancer gene therapy products from abroad. The implication being that too strict of regulations often results in the treatment of patients with unapproved therapies, as is similarly observed with cell therapy in the US [@bib2]. Appropriate legislation can prompt healthy provision of new therapies to patients suffering from intractable diseases.
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